


1) Cases of antibiotic resistant bacterial infections in the hospital from 2010 onward, by calendar year.

Please see Figures 1-4 below that highlight the data for antibiotic resistant infections by calendar year. The data supplied has been provided as far back as possible. The data provided shows all cases identified in the Exeter microbiology laboratory not just cases that were hospital in-patients. These include:

- *Pseudomonas*
- *E.coli*
- Non *E.coli* Enterobacteriaceae
- *Staphylococcus aureus*

Figure 1


Pseudomonas - Blood Culture Isolates



Year	Quarter	Antibiotic	Sensitive	Sensitivity %	Resistant	Resistance %	Total	Quarter
2012	Q4	Ciprofloxacin	6	75.00%	2	25.00%	8	8
		Gentamicin	7	87.50%	1	12.50%	8	
		Pip/Tazo	8	100.00%	0	0.00%	8	
		Meropenem	7	87.50%	1	12.50%	8	
2013	Q1	Ciprofloxacin	8	88.89%	1	11.11%	9	9
		Gentamicin	9	100.00%	0	0.00%	9	
		Pip/Tazo	8	88.89%	1	11.11%	9	
		Meropenem	8	88.89%	1	11.11%	9	
2013	Q2	Ciprofloxacin	4	80.00%	1	20.00%	5	5
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	3	60.00%	2	40.00%	5	
		Meropenem	4	80.00%	1	20.00%	5	
2013	Q3	Ciprofloxacin	6	100.00%	0	0.00%	6	6
		Gentamicin	6	100.00%	0	0.00%	6	
		Pip/Tazo	6	100.00%	0	0.00%	6	
		Meropenem	5	83.33%	1	16.67%	6	
2013	Q4	Ciprofloxacin	4	100.00%	0	0.00%	4	4
		Gentamicin	4	100.00%	0	0.00%	4	
		Pip/Tazo	4	100.00%	0	0.00%	4	
		Meropenem	4	100.00%	0	0.00%	4	
2014	Q1	Ciprofloxacin	4	80.00%	1	20.00%	5	6
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	5	100.00%	0	0.00%	5	
		Meropenem	4	80.00%	1	20.00%	5	
2014	Q2	Ciprofloxacin	5	100.00%	0	0.00%	5	5
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	5	100.00%	0	0.00%	5	
		Meropenem	4	80.00%	1	20.00%	5	
2014	Q3	Ciprofloxacin	5	100.00%	0	0.00%	5	5
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	5	100.00%	0	0.00%	5	
		Meropenem	5	100.00%	1	20.00%	5	
2014	Q4	Ciprofloxacin	5	83.33%	1	16.67%	6	6
		Gentamicin	6	100.00%	0	0.00%	6	
		Pip/Tazo	6	100.00%	0	0.00%	6	
		Meropenem	6	100.00%	0	0.00%	6	
2015	Q1	Ciprofloxacin	4	100.00%	0	0.00%	4	4
		Gentamicin	4	100.00%	0	0.00%	4	
		Pip/Tazo	4	100.00%	0	0.00%	4	
		Meropenem	4	100.00%	0	0.00%	4	
2015	Q2	Ciprofloxacin	3	100.00%	0	0.00%	3	3
		Gentamicin	2	66.67%	1	33.33%	3	
		Pip/Tazo	3	100.00%	0	0.00%	3	
		Meropenem	1	33.33%	2	66.67%	3	
2015	Q3	Ciprofloxacin	2	100.00%	0	0.00%	2	2
		Gentamicin	2	100.00%	0	0.00%	2	
		Pip/Tazo	2	100.00%	0	0.00%	2	
		Meropenem	2	100.00%	0	0.00%	2	
2015	Q4	Ciprofloxacin	4	100.00%	0	0.00%	4	4
		Gentamicin	4	100.00%	0	0.00%	4	
		Pip/Tazo	4	100.00%	0	0.00%	4	
		Meropenem	4	100.00%	0	0.00%	4	

Figure 2

Escherichia coli - Blood Culture Isolates




Year	Quarter	Antibiotic	Sensitive	Sensitivity %	Resistant	Resistance %	Total	Quarter	ESBL +ve	% Res to Amox + Gent
2012	Q4	Amoxicillin	20	32.26%	42	67.74%	62	62	6	8.06%
		Augmentin	49	79.03%	13	20.97%	62			
		Ciprofloxacin	56	90.32%	6	9.68%	62			
		Doxycycline	41	68.33%	19	31.67%	60			
		Gentamicin	56	90.32%	6	9.68%	62			
		Pip/Tazo	53	85.48%	9	14.52%	62			
		Trimethoprim	36	58.06%	26	41.94%	62			
		Meropenem	62	100.00%	0	0.00%	62			
Amp C Beta-Lactamase	0	0.00%	62	100.00%	62					
2013	Q1	Amoxicillin	21	32.31%	44	67.69%	65	65	2	13.85%
		Augmentin	52	80.00%	13	20.00%	65			
		Ciprofloxacin	56	86.15%	9	13.85%	65			
		Doxycycline	44	67.69%	21	32.31%	65			
		Gentamicin	55	84.62%	10	15.38%	65			
		Pip/Tazo	63	96.92%	2	3.08%	65			
		Trimethoprim	35	53.85%	30	46.15%	65			
		Meropenem	62	100.00%	0	0.00%	62			
Amp C Beta-Lactamase	1	1.54%	64	98.46%	65					
2013	Q2	Amoxicillin	20	37.74%	33	62.26%	53	53	1	3.77%
		Augmentin	41	77.36%	12	22.64%	53			
		Ciprofloxacin	49	92.45%	4	7.55%	53			
		Doxycycline	31	58.49%	22	41.51%	53			
		Gentamicin	51	96.23%	2	3.77%	53			
		Pip/Tazo	51	96.23%	2	3.77%	53			
		Trimethoprim	35	66.04%	18	33.96%	53			
		Meropenem	53	100.00%	0	0.00%	53			
Amp C Beta-Lactamase	0	0.00%	53	100.00%	53					
2013	Q3	Amoxicillin	14	25.00%	42	75.00%	56	56	3	19.64%
		Augmentin	37	66.07%	19	33.93%	56			
		Ciprofloxacin	48	85.71%	8	14.29%	56			
		Doxycycline	34	60.71%	22	39.29%	56			
		Gentamicin	44	78.57%	12	21.43%	56			
		Pip/Tazo	49	87.50%	7	12.50%	56			
		Trimethoprim	27	48.21%	29	51.79%	56			
		Meropenem	56	100.00%	0	0.00%	56			
Amp C Beta-Lactamase	0	0.00%	56	100.00%	56					
2013	Q4	Amoxicillin	23	38.33%	37	61.67%	60	60	1	3.33%
		Augmentin	47	78.33%	13	21.67%	60			
		Ciprofloxacin	58	96.67%	2	3.33%	60			
		Doxycycline	42	70.00%	18	30.00%	60			
		Gentamicin	58	96.67%	2	3.33%	60			
		Pip/Tazo	56	93.33%	4	6.67%	60			
		Trimethoprim	45	75.00%	15	25.00%	60			
		Meropenem	60	100.00%	0	0.00%	60			
Amp C Beta-Lactamase	3	5.00%	57	95.00%	60					

2014	Q1	Amoxicillin	16	29.09%	39	70.91%	55	55	4	5.45%
		Augmentin	27	49.09%	28	50.91%	55			
		Ciprofloxacin	49	89.09%	6	10.91%	55			
		Doxycycline	35	63.64%	20	36.36%	55			
		Gentamicin	51	92.73%	4	7.27%	55			
		Pip/Tazo	51	92.73%	4	7.27%	55			
		Trimethoprim	29	52.73%	26	47.27%	55			
		Meropenem	55	100.00%	0	0.00%	55			
Amp C Beta-Lactamase	4	7.27%	51	92.73%	55					
2014	Q2	Amoxicillin	27	41.54%	38	58.46%	65	65	5	7.69%
		Augmentin	41	63.08%	24	36.92%	65			
		Ciprofloxacin	58	89.23%	7	10.77%	65			
		Doxycycline	46	70.77%	19	29.23%	65			
		Gentamicin	60	92.31%	5	7.69%	65			
		Pip/Tazo	58	89.23%	7	10.77%	65			
		Trimethoprim	40	61.54%	25	38.46%	65			
		Meropenem	65	100.00%	0	0.00%	65			
Amp C Beta-Lactamase	1	1.54%	64	98.46%	65					
2014	Q3	Amoxicillin	17	24.29%	42	60.00%	70	70	4	10.00%
		Augmentin	31	44.29%	19	27.14%	70			
		Ciprofloxacin	65	92.86%	8	11.43%	70			
		Doxycycline	44	62.86%	22	31.43%	70			
		Gentamicin	63	90.00%	12	17.14%	70			
		Pip/Tazo	64	91.43%	7	10.00%	70			
		Trimethoprim	34	48.57%	29	41.43%	70			
		Meropenem	70	100.00%	0	0.00%	70			
Amp C Beta-Lactamase	7	10.00%	56	80.00%	70					
2014	Q4	Amoxicillin	38	66.67%	19	33.33%	57	57	2	7.02%
		Augmentin	42	73.68%	15	26.32%	57			
		Ciprofloxacin	54	94.74%	3	5.26%	57			
		Doxycycline	43	75.44%	14	24.56%	57			
		Gentamicin	53	92.98%	4	7.02%	57			
		Pip/Tazo	56	98.25%	1	1.75%	57			
		Trimethoprim	40	72.73%	15	27.27%	55			
		Meropenem	57	100.00%	0	0.00%	57			
Amp C Beta-Lactamase	6	10.53%	51	89.47%	57					
2015	Q1	Amoxicillin	35	49.30%	36	50.70%	71	72	1	8.33%
		Augmentin	56	77.78%	16	22.22%	72			
		Ciprofloxacin	63	87.50%	9	12.50%	72			
		Doxycycline	56	77.78%	16	22.22%	72			
		Gentamicin	63	87.50%	9	12.50%	72			
		Pip/Tazo	65	90.28%	7	9.72%	72			
		Trimethoprim	50	69.44%	22	30.56%	72			
		Meropenem	72	100.00%	0	0.00%	72			
Amp C Beta-Lactamase	1	1.39%	71	98.61%	72					
2015	Q2	Amoxicillin	21	31.34%	46	68.66%	67	67	5	4.48%
		Augmentin	44	65.67%	23	34.33%	67			
		Ciprofloxacin	59	88.06%	8	11.94%	67			
		Doxycycline	44	65.67%	23	34.33%	67			
		Gentamicin	64	95.52%	3	4.48%	67			
		Pip/Tazo	61	91.04%	6	8.96%	67			
		Trimethoprim	33	49.25%	34	50.75%	67			
		Meropenem	67	100.00%	0	0.00%	67			
Amp C Beta-Lactamase	5	7.46%	62	92.54%	67					
2015	Q3	Amoxicillin	34	53.13%	30	46.88%	64	63	1	4.76%
		Augmentin	50	78.13%	14	21.88%	64			
		Ciprofloxacin	54	84.38%	10	15.63%	64			
		Doxycycline	47	73.44%	17	26.56%	64			
		Gentamicin	61	95.31%	3	4.69%	64			
		Pip/Tazo	60	93.75%	4	6.25%	64			
		Trimethoprim	42	65.63%	22	34.38%	64			
		Meropenem	64	100.00%	0	0.00%	64			
Amp C Beta-Lactamase	1	1.56%	63	98.44%	64					
2015	Q4	Amoxicillin	36	43.37%	47	56.63%	83	82	3	6.10%
		Augmentin	56	67.47%	27	32.53%	83			
		Ciprofloxacin	71	85.54%	12	14.46%	83			
		Doxycycline	52	62.65%	31	37.35%	83			
		Gentamicin	77	92.77%	6	7.23%	83			
		Pip/Tazo	76	91.57%	7	8.43%	83			
		Trimethoprim	46	55.42%	37	44.58%	83			
		Meropenem	83	100.00%	0	0.00%	83			
Amp C Beta-Lactamase	3	3.61%	80	96.39%	83					

Figure 3

Enterobacteriaceae / Non E-Coli - Blood Culture Isolates




Year	Quarter	Antibiotic	Sensitive	Sensitivity %	Resistant	Resistance %	Total	Quarter
2012	Q4	Amoxicillin	3	60.00%	2	40.00%	5	5
		Augmentin	3	60.00%	2	40.00%	5	
		Ciprofloxacin	4	100.00%	0	0.00%	4	
		Doxycycline	2	40.00%	3	60.00%	5	
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	4	80.00%	1	20.00%	5	
		Trimethoprim	2	40.00%	3	60.00%	5	
2013	Q1	Amoxicillin	3	30.00%	7	70.00%	10	11
		Augmentin	8	72.73%	3	27.27%	11	
		Ciprofloxacin	10	90.91%	1	9.09%	11	
		Doxycycline	5	45.45%	6	54.55%	11	
		Gentamicin	9	81.82%	2	18.18%	11	
		Pip/Tazo	11	100.00%	0	0.00%	11	
		Trimethoprim	3	27.27%	8	72.73%	11	
2013	Q2	Amoxicillin	1	20.00%	4	80.00%	5	6
		Augmentin	1	20.00%	4	80.00%	5	
		Ciprofloxacin	4	80.00%	1	20.00%	5	
		Doxycycline	3	60.00%	2	40.00%	5	
		Gentamicin	5	100.00%	0	0.00%	5	
		Pip/Tazo	5	100.00%	0	0.00%	5	
		Trimethoprim	2	40.00%	3	60.00%	5	
2013	Q3	Amoxicillin	3	37.50%	5	62.50%	8	8
		Augmentin	3	37.50%	5	62.50%	8	
		Ciprofloxacin	7	87.50%	1	12.50%	8	
		Doxycycline	5	62.50%	3	37.50%	8	
		Gentamicin	8	100.00%	0	0.00%	8	
		Pip/Tazo	8	100.00%	0	0.00%	8	
		Trimethoprim	3	37.50%	5	62.50%	8	
2013	Q4	Amoxicillin	3	37.50%	5	62.50%	8	8
		Augmentin	5	62.50%	3	37.50%	8	
		Ciprofloxacin	8	100.00%	0	0.00%	8	
		Doxycycline	4	50.00%	4	50.00%	8	
		Gentamicin	5	62.50%	3	37.50%	8	
		Pip/Tazo	8	100.00%	0	0.00%	8	
		Trimethoprim	4	50.00%	4	50.00%	8	

2014	Q1	Amoxicillin	3	37.50%	5	62.50%	8	8
		Augmentin	4	50.00%	4	50.00%	8	
		Ciprofloxacin	8	100.00%	0	0.00%	8	
		Doxycycline	5	62.50%	3	37.50%	8	
		Gentamicin	8	100.00%	0	0.00%	8	
		Pip/Tazo	8	100.00%	0	0.00%	8	
		Trimethoprim	4	50.00%	4	50.00%	8	
2014	Q2	Amoxicillin	8	50.00%	8	50.00%	16	16
		Augmentin	11	68.75%	5	31.25%	16	
		Ciprofloxacin	15	93.75%	1	6.25%	16	
		Doxycycline	5	31.25%	11	68.75%	16	
		Gentamicin	15	93.75%	1	6.25%	16	
		Pip/Tazo	15	93.75%	1	6.25%	16	
		Trimethoprim	10	62.50%	6	37.50%	16	
2014	Q3	Amoxicillin	1	10.00%	9	90.00%	10	10
		Augmentin	4	40.00%	6	60.00%	10	
		Ciprofloxacin	10	100.00%	0	0.00%	10	
		Doxycycline	7	70.00%	3	30.00%	10	
		Gentamicin	10	100.00%	0	0.00%	10	
		Pip/Tazo	10	100.00%	0	0.00%	10	
		Trimethoprim	9	90.00%	1	10.00%	10	
2014	Q4	Amoxicillin	5	50.00%	5	50.00%	10	11
		Augmentin	7	70.00%	3	30.00%	10	
		Ciprofloxacin	10	100.00%	0	0.00%	10	
		Doxycycline	5	50.00%	5	50.00%	10	
		Gentamicin	10	100.00%	0	0.00%	10	
		Pip/Tazo	10	100.00%	0	0.00%	10	
		Trimethoprim	7	70.00%	3	30.00%	10	
		Meropenem	10	100.00%	0	0.00%	10	
2015	Q1	Amoxicillin	5	83.33%	1	16.67%	6	6
		Augmentin	6	100.00%	0	0.00%	6	
		Ciprofloxacin	6	100.00%	0	0.00%	6	
		Doxycycline	1	16.67%	5	83.33%	6	
		Gentamicin	6	100.00%	0	0.00%	6	
		Pip/Tazo	6	100.00%	0	0.00%	6	
		Trimethoprim	4	66.67%	2	33.33%	6	
		Meropenem	6	100.00%	0	0.00%	6	
2015	Q2	Amoxicillin	4	40.00%	6	60.00%	10	10
		Augmentin	6	60.00%	4	40.00%	10	
		Ciprofloxacin	10	100.00%	0	0.00%	10	
		Doxycycline	6	60.00%	4	40.00%	10	
		Gentamicin	10	100.00%	0	0.00%	10	
		Pip/Tazo	10	100.00%	0	0.00%	10	
		Trimethoprim	8	80.00%	2	20.00%	10	
		Meropenem	10	100.00%	0	0.00%	10	
2015	Q3	Amoxicillin	3	42.86%	4	57.14%	7	7
		Augmentin	4	57.14%	3	42.86%	7	
		Ciprofloxacin	6	85.71%	1	14.29%	7	
		Doxycycline	2	28.57%	5	71.43%	7	
		Gentamicin	7	100.00%	0	0.00%	7	
		Pip/Tazo	7	100.00%	0	0.00%	7	
		Trimethoprim	1	14.29%	6	85.71%	7	
		Meropenem	7	100.00%	0	0.00%	7	
2015	Q4	Amoxicillin	5	45.45%	6	54.55%	11	11
		Augmentin	6	54.55%	5	45.45%	11	
		Ciprofloxacin	11	100.00%	0	0.00%	11	
		Doxycycline	6	54.55%	5	45.45%	11	
		Gentamicin	11	100.00%	0	0.00%	11	
		Pip/Tazo	10	90.91%	1	9.09%	11	
		Trimethoprim	4	36.36%	7	63.64%	11	
		Meropenem	11	100.00%	0	0.00%	11	

Figure 4 -

Staphylococcus aureus - All Requestors / All Sites



*This data does **not** include specimens sent for MRSA testing only

Year	Quarter	Antibiotic	Sensitive	Sensitivity %	Resistant	Resistance %	Total	Quarter
2012	Q4	Clindamycin	1332	87.40%	192	12.60%	1524	1715
		Doxycycline	1479	97.17%	43	2.83%	1522	
		Erythromycin	1422	85.15%	248	14.85%	1670	
		Pencillin	323	20.61%	1244	79.39%	1567	
		Trimethoprim	168	86.15%	27	13.85%	195	
		Flucloxacillin	1641	95.74%	73	4.26%	1714	
		Fusidic Acid	1529	91.56%	141	8.44%	1670	
		Mupiricin	1516	99.48%	8	0.52%	1524	
2013	Q1	Clindamycin	1258	87.67%	177	12.33%	1435	1634
		Doxycycline	1366	95.66%	62	4.34%	1428	
		Erythromycin	1361	85.65%	228	14.35%	1589	
		Pencillin	360	24.37%	1117	75.63%	1477	
		Trimethoprim	194	86.22%	31	13.78%	225	
		Flucloxacillin	1561	95.71%	70	4.29%	1631	
		Fusidic Acid	1469	92.51%	119	7.49%	1588	
		Mupiricin	1420	99.02%	14	0.98%	1434	
2013	Q2	Clindamycin	1238	88.87%	155	11.13%	1393	1592
		Doxycycline	1326	95.60%	61	4.40%	1387	
		Erythromycin	1336	86.92%	201	13.08%	1537	
		Pencillin	339	23.48%	1105	76.52%	1444	
		Trimethoprim	198	87.61%	28	12.39%	226	
		Flucloxacillin	1526	95.97%	64	4.03%	1590	
		Fusidic Acid	1422	92.52%	115	7.48%	1537	
		Mupiricin	1380	99.07%	13	0.93%	1393	
2013	Q3	Clindamycin	1330	89.26%	160	10.74%	1490	1698
		Doxycycline	1432	96.89%	46	3.11%	1478	
		Erythromycin	1442	87.71%	202	12.29%	1644	
		Pencillin	345	22.64%	1179	77.36%	1524	
		Trimethoprim	180	89.11%	22	10.89%	202	
		Flucloxacillin	1614	96.24%	63	3.76%	1677	
		Fusidic Acid	1509	91.79%	135	8.21%	1644	
		Mupiricin	1484	99.60%	6	0.40%	1490	
2013	Q4	Clindamycin	1307	88.13%	176	11.87%	1483	1659
		Doxycycline	1410	95.27%	70	4.73%	1480	
		Erythromycin	1365	84.47%	251	15.53%	1616	
		Pencillin	340	22.32%	1183	77.68%	1523	
		Trimethoprim	167	84.77%	30	15.23%	197	
		Flucloxacillin	1589	96.01%	66	3.99%	1655	
		Fusidic Acid	1484	91.89%	131	8.11%	1615	
		Mupiricin	1466	98.92%	16	1.08%	1482	

2014	Q1	Clindamycin	1226	86.64%	189	13.36%	1415	1614
		Doxycycline	1356	95.83%	59	4.17%	1415	
		Erythromycin	1330	84.66%	241	15.34%	1571	
		Pencillin	332	22.87%	1120	77.13%	1452	
		Trimethoprim	189	85.14%	33	14.86%	222	
		Flucloxacillin	1541	95.89%	66	4.11%	1607	
		Fusidic Acid	1441	91.84%	128	8.16%	1569	
		Mupiricin	1402	99.29%	10	0.71%	1412	
2014	Q2	Clindamycin	1307	89.77%	149	10.23%	1456	1666
		Doxycycline	1357	93.14%	100	6.86%	1457	
		Erythromycin	1406	87.22%	206	12.78%	1612	
		Pencillin	359	23.84%	1147	76.16%	1506	
		Trimethoprim	182	88.78%	23	11.22%	205	
		Flucloxacillin	1607	96.69%	55	3.31%	1662	
		Fusidic Acid	1482	91.94%	130	8.06%	1612	
		Mupiricin	1446	99.38%	9	0.62%	1455	
2014	Q3	Clindamycin	1404	87.31%	204	12.69%	1608	1819
		Doxycycline	1512	94.15%	94	5.85%	1606	
		Erythromycin	1490	84.76%	268	15.24%	1758	
		Pencillin	161	22.27%	562	77.73%	723	
		Trimethoprim	209	92.07%	18	7.93%	227	
		Flucloxacillin	1760	97.29%	49	2.71%	1809	
		Fusidic Acid	1607	91.41%	151	8.59%	1758	
		Mupiricin	1592	99.00%	16	1.00%	1608	
2014	Q4	Clindamycin	1608	88.55%	208	11.45%	1816	2004
		Doxycycline	1730	95.32%	85	4.68%	1815	
		Erythromycin	1680	85.80%	278	14.20%	1958	
		Pencillin	46	18.47%	203	81.53%	249	
		Trimethoprim	224	89.24%	27	10.76%	251	
		Flucloxacillin	1948	97.40%	52	2.60%	2000	
		Fusidic Acid	1779	90.86%	179	9.14%	1958	
		Mupiricin	1805	99.39%	11	0.61%	1816	
2015	Q1	Clindamycin	1468	85.15%	256	14.85%	1724	1985
		Doxycycline	1622	94.19%	100	5.81%	1722	
		Erythromycin	1590	83.77%	308	16.23%	1898	
		Pencillin	82	19.43%	340	80.57%	422	
		Trimethoprim	366	86.73%	56	13.27%	422	
		Flucloxacillin	1806	92.85%	139	7.15%	1945	
		Fusidic Acid	1741	91.73%	179	9.43%	1898	
		Mupiricin	1712	99.36%	11	0.64%	1723	
2015	Q2	Clindamycin	1301	85.48%	221	14.52%	1522	1725
		Doxycycline	1434	94.22%	88	5.78%	1522	
		Erythromycin	1400	83.88%	269	16.12%	1669	
		Pencillin	50	19.23%	210	80.77%	260	
		Trimethoprim	238	90.84%	24	9.16%	262	
		Flucloxacillin	1648	96.49%	60	3.51%	1708	
		Fusidic Acid	1512	90.59%	157	9.41%	1669	
		Mupiricin	1504	98.82%	18	1.18%	1522	
2015	Q3	Clindamycin	1397	85.60%	235	14.40%	1632	1871
		Doxycycline	1553	95.16%	79	4.84%	1632	
		Erythromycin	1529	84.62%	278	15.38%	1807	
		Pencillin	86	22.81%	291	77.19%	377	
		Trimethoprim	336	88.65%	43	11.35%	379	
		Flucloxacillin	1771	94.60%	101	5.40%	1872	
		Fusidic Acid	1645	90.98%	163	9.02%	1808	
		Mupiricin	1625	99.51%	8	0.49%	1633	
2015	Q4	Clindamycin	1351	82.99%	277	17.01%	1628	1838
		Doxycycline	1538	94.65%	87	5.35%	1625	
		Erythromycin	1446	81.37%	331	18.63%	1777	
		Pencillin	93	20.31%	365	79.69%	458	
		Trimethoprim	385	84.25%	72	15.75%	457	
		Flucloxacillin	1710	93.09%	127	6.91%	1837	
		Fusidic Acid	1641	92.45%	134	7.55%	1775	
		Mupiricin	1608	98.89%	18	1.11%	1626	

2) Figures of Carbapenem-resistant enterobacteriaceae (CPE)

For cases of CPE specifically, only a small number have been identified and are as follows:

Table 1

		Organism	CPE detected
2010	1	<i>Escherichia coli</i>	NDM and OXA-48
2011	0		
2012	1	<i>Klebsiella pneumoniae</i>	IMP
2013	0		
2014	2	<i>Klebsiella pneumoniae</i> <i>Klebsiella pneumoniae</i>	NDM NDM
2015	1	<i>Escherichia coli</i>	OXA-48
2016	1	<i>Enterobacter cloacae</i>	OXA-48

Fatalities - None of these cases were fatal.

3) Figures of PVL-MRSA cases


We do not routinely test for PVL. PVL tests are not undertaken in the local laboratory but when clinical symptoms are suggestive of PVL, samples are sent away to, and PVL tests requested from, a PHE reference laboratory. Some tests are undertaken as part of research or surveillance projects and do not necessarily represent clinical infection.

The number of cases identified are shown at Figure 5

Fatalities – There have been no fatalities resulting from these cases.

Figure 5

Staphylococcus aureus - PVL Sendaways



*This data does not include specimens sent for MRSA testing only

Year	Quarter	Hospital Pos	Hospital %	GP Positive	GP %	Marine Pos	Marine %	Total Positive	Total Sent	Total Positive %
2012	Q4	0	0.00%	2	50.00%	0	0.00%	2	4	50.00%
2013	Q1	0	0.00%	1	20.00%	0	0.00%	1	5	20.00%
2013	Q2	6	15.38%	4	10.26%	1	2.56%	11	39	28.21%
2013	Q3	5	4.63%	4	3.70%	1	0.93%	11	108	10.19%
2013	Q4	8	9.88%	9	11.11%	0	0.00%	17	81	20.99%
2014	Q1	0	0.00%	0	0.00%	0	0.00%	0	8	0.00%
2014	Q2	0	0.00%	0	0.00%	0	0.00%	0	0	0.00%
2014	Q3	0	0.00%	0	0.00%	1	14.29%	1	7	14.29%
2014	Q4	0	0.00%	0	0.00%	0	0.00%	0	3	0.00%
2015	Q1	1	5.00%	0	0.00%	3	15.00%	4	20	20.00%
2015	Q2	0	0.00%	0	0.00%	0	0.00%	0	0	0.00%
2015	Q3	0	0.00%	0	0.00%	0	0.00%	0	4	0.00%
2015	Q4	2	25.00%	0	0.00%	1	12.50%	3	8	37.50%

4) Figures of *C.difficile* cases

These data are available from the Public Health England website as part of mandatory national surveillance.

Fatalities – The data below relates to on *Clostridium difficile* being cited on Part 1 of death certificates

Year	Total
2010	3
2011	6
2012	2
2013	0
2014	0
2015	1

5) Figures of *E.coli*

These figures are included as part of the response to the first part of the request and can be seen in Figure 2.

Fatalities - The data below relates to deaths that were associated with *E.coli* sepsis that was diagnosed from specimens taken prior to, or on admission to hospital, i.e. none of these infections were hospital acquired.

Year	Total
2010	0
2011	2
2012	2
2013	2
2014	0
2015	0

